FOXO4-DRI

Overview

FOXO4-DRI is a synthetic peptide developed in 2017 by the laboratory of Peter de Keizer at Erasmus University Medical Center (Rotterdam) as a proof-of-concept senolytic tool. It was designed to disrupt the protein–protein interaction between FOXO4 and p53 inside senescent cells, tipping the balance toward p53-driven apoptosis and thereby selectively clearing senescent cells from tissues.

The design uses the D-retro-inverso (DRI) strategy: the peptide is synthesized from D-amino acids in reverse sequence relative to the natural FOXO4 segment. This preserves the topological arrangement of side chains relative to the original L-amino acid epitope while rendering the peptide dramatically resistant to natural proteases. DRI peptides typically retain target-binding activity while extending in-vivo stability by orders of magnitude.

The initial publication showed that systemic FOXO4-DRI selectively killed senescent cells in naturally aged mice, improving markers of renal function, fur density, and fitness. This generated substantial attention in the aging research community and spurred broader interest in senolytic peptides and small molecules.

Structure / Chemistry

• Class: D-retro-inverso peptide
• Parent sequence: Human FOXO4 segment containing the p53-interaction motif
• Synthesis: Made from D-amino acids in reversed order relative to the natural L-peptide
• Typical length: Short (often around 5–10 residues in published designs), attached to a cell-penetrating segment
• Cell-penetrating delivery: Commonly conjugated to a TAT- or penetratin-like sequence to cross plasma membranes

The DRI approach produces a peptide essentially invisible to most endogenous proteases, which greatly extends systemic half-life relative to the L-peptide equivalent. Cell-penetrating conjugation is typically required for intracellular targets such as the FOXO4–p53 interaction.

Mechanism of Action

FOXO4-DRI targets a specific interaction in senescent cells:

• Disruption of FOXO4–p53 binding in the nuclei of senescent cells
• Release of p53 from its sequestered, senescence-supporting role
• Relocalization of p53 to mitochondria where it can initiate apoptosis
• Selective senolysis of cells expressing elevated FOXO4 and chronic p53 stress (a hallmark of senescence)
• Relative sparing of non-senescent cells, in which the FOXO4–p53 interaction is less central to survival

The result, in preclinical models, is targeted removal of senescent cells without the broader cytotoxicity of conventional apoptotic inducers. This represents a mechanistically distinct class of senolytic — protein–protein interaction disruption rather than kinase inhibition or Bcl-2 family antagonism.

Research Summary

Human clinical data are absent; the compound remains a preclinical research tool.

Pharmacokinetics

The DRI architecture provides substantial protease resistance, producing plasma half-lives in rodents on the order of hours — far longer than the L-peptide equivalent. Cell-penetrating conjugation supports intracellular access. Administration in published studies has used intravenous and intraperitoneal routes.

Tissue distribution favors organs with active senescent cell accumulation under stress conditions (kidney, liver, skin, and various fibrotic tissues). Clearance is primarily renal for intact peptide and proteolytic where D-stereochemistry is gradually compromised at termini.

Common Discussion Topics

• Design rationale of D-retro-inverso peptides
• FOXO4-DRI positioning among senolytics (dasatinib + quercetin, navitoclax, etc.)
• Translational challenges from rodent to human studies
• Specificity of the FOXO4–p53 interaction across tissues
• Potential off-target effects in rapidly proliferating tissues

Related Compounds

• Klotho — anti-aging hormone with overlapping research themes
• Humanin — mitochondrial cytoprotective peptide
• Epithalon — Khavinson peptide with aging research focus
• Cerebrolysin — neurotrophic peptide preparation
• FGF21 — metabolic hormone relevant to aging biology

Educational information only. FOXO4-DRI is a preclinical research peptide not approved for human use. This article does not constitute medical or dosing advice.